에이비엘바이오/Compass Therapeutics tovecimig(DLL4xVEGF-A)의 담도암(BTC) Phase 2/3(COMPANION-2)에서 사망…

(기존 1Q26에서 late 1Q26로 연장됨) Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of overall survival (OS) and progression-free survival (PFS) are expected in late Q1 2026. https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-reports-third-quarter-2025-financial